Rare Ovarian Tumors
Main Article Content
ABSTRACT
Ovarian cancer is the eighth most common cancer among women globally. There are currently no feasible screening strategies for this disease. Diagnosis, treatment, surveillance, and survival of patients have improved over the years with advancements in radiology, pathology, genomics, and molecular biology. Individualized care incorporates precision surgery to limit morbidity. Germline genetic analysis and identification of somatic mutations in tumor tissue provide data for the use of targeted agents and immunotherapy. High grade serous carcinomas comprise 70% of diagnoses, but rare ovarian cancers affect women characterized by a wide spectrum of ages and risk factors. This chapter discusses the pathologic and molecular features of these cancers. The text also highlights the evolution of treatment to modern-day standards and the landmark trials that contributed to these changes.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.